TABLE 5.

The demographic and clinical findings of patients with chronic idiopathic urticaria diagnosed with COVID‐19 in our cohort and in the literature

Study/Author	Age, gender	Concomitant disease	Drug used for the treatment of urticaria, duration	Drug used for the treatment of COVID‐19	COVID‐19 diagnostic tools	Hospitalization due to COVID‐19	Urticaria severity due to COVID‐19, UAS7 scores before/during COVID‐19, change in %	Non‐urticarial cutaneous manifestation
Present cohort, Patient 1	55 year‐old, female	No	Loratadine 10 mg/day, 2 years	Hydroxychloroquine 400 mg twice on day 1, followed by 400 mg/day for 4 days Enoxaparine sodium 4000 IU/day subcutaneously for 7 days	Positive PCR test and chest CT findings	Yes, 7 days	Remained stable, UAS7 = 0/0	Chilblains on lower legs
Present cohort, Patient 2	37 year‐old, female	Asthma bronchiale	Cetirizine 10 mg/day, 2 years	Hydroxychloroquine 400 mg twice on day 1, followed by 400 mg/day for 4 days	Positive PCR test	No, at‐home treatment	Exacerbated, UAS7 = 6/20, increased to 3.3‐fold	Chilblains on fingers
Criado et al 13	57 year‐old, female	No	Bilastine 80 mg/day, not defined	Amoxicillin‐clavulanate for 7 days	Positive PCR test and chest CT findings	No, at‐home treatment	Exacerbated, UAS7 = 6/42 increased to 7‐fold	Not defined

Abbreviations: CT, computed tomography; PCR, polymerase chain reaction; UAS7, weekly urticaria activity score.